uniQure Investor Relations Material
Latest events
Study Update
uniQure
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from uniQure N.V.
Access all reports
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Through its adeno-associated virus (AAV) based gene therapy platform, the company develops proprietary power gene therapies that can be used to treat diseases with a high unmet need. Its lead program is focused on Hemophilia B and Huntington's disease.
Key slides for uniQure N.V.
Study Update
uniQure N.V.
Study Update
uniQure N.V.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
QURE
Country
🇺🇸 United States